Performs comparative bioavailability calculations for Average Bioequivalence with Expanding Limits (ABEL). Implemented are 'Method A' and 'Method B' and the detection of outliers. If the design allows, assessment of the empiric Type I Error and iteratively adjusting alpha to control the consumer risk. Average Bioequivalence - optionally with a tighter (narrow therapeutic index drugs) or wider acceptance range (Gulf Cooperation Council, South Africa: Cmax) - is implemented as well.
|Author||Helmut Schütz [aut, cre] (<https://orcid.org/0000-0002-1167-7880>), Michael Tomashevskiy [ctb], Detlew Labes [ctb] (<https://orcid.org/0000-0003-2169-426X>)|
|Maintainer||Helmut Schütz <[email protected]>|
|License||GPL (>= 3)|
|Package repository||View on CRAN|
Install the latest version of this package by entering the following in R:
Any scripts or data that you put into this service are public.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.